INSUD PHARMA Secures Major Funding in Global Expansion Drive: Revolutionizing Pharma Across 96 Countries

Insud Pharma, a global leader in the pharmaceutical industry, has recently announced a substantial funding round aimed at enhancing its innovative capabilities and expanding its market reach. With a remarkable focus on delivering high-quality active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs), the company successfully raised €100 million ($105 million) to further its mission of improving global health outcomes. This strategic funding will be utilized to bolster its research and development initiatives, particularly within its three committed business areas: Industrial (Chemo), Branded (Exeltis), and Biotech (mAbxience). With over 7,300 professionals operating across more than 50 countries, Insud Pharma's expansive network of 18 manufacturing facilities and 15 R&D centers positions it uniquely to tackle diverse healthcare challenges across Europe, America, Asia, and Africa. The funding will specifically support the development of innovative therapies and scalable production processes to meet the rising global demand for affordable medical solutions. Insud Pharma's philosophy centers on sustainable development and accessibility, reflecting its dedication to not just advancing pharmaceutical technology but also ensuring that quality healthcare remains within reach for all communities. By significantly investing in R&D, Insud Pharma is setting the stage for breakthroughs in both human and animal health, thereby furthering its commitment to enhancing the quality of life on a global scale. This funding marks a pivotal moment for Insud Pharma, as it continues to lead in innovation and responsiveness in a rapidly evolving healthcare landscape.